Victory Capital Management Inc. cut its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 63.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,864 shares of the biopharmaceutical company’s stock after selling 4,978 shares during the period. Victory Capital Management Inc.’s holdings in Vanda Pharmaceuticals were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also bought and sold shares of VNDA. Pacer Advisors Inc. bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $138,000. Zebra Capital Management LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $170,000. DekaBank Deutsche Girozentrale increased its position in Vanda Pharmaceuticals by 23.3% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 10,600 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 2,000 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $272,000. Finally, Balyasny Asset Management LLC bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $285,000.
A number of analysts recently commented on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 target price for the company. in a research report on Saturday, October 5th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st. ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Citigroup raised Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $26.71.
Shares of Vanda Pharmaceuticals stock opened at $12.71 on Friday. Vanda Pharmaceuticals Inc. has a one year low of $11.83 and a one year high of $33.44. The firm has a market capitalization of $659.53 million, a price-to-earnings ratio of 23.81 and a beta of 0.32. The business has a 50-day simple moving average of $13.65 and a 200 day simple moving average of $14.95.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.24. The business had revenue of $59.06 million during the quarter, compared to the consensus estimate of $54.19 million. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The company’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.15 EPS. On average, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post 0.32 earnings per share for the current fiscal year.
In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 2,575 shares of Vanda Pharmaceuticals stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $14.69, for a total transaction of $37,826.75. Following the completion of the transaction, the senior vice president now owns 57,425 shares in the company, valued at approximately $843,573.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard W. Dugan sold 15,000 shares of Vanda Pharmaceuticals stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.85, for a total value of $222,750.00. Following the transaction, the director now owns 50,770 shares of the company’s stock, valued at approximately $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by insiders.
Vanda Pharmaceuticals Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.